Virax Biolabs GroupVRAX
13F holders, Q1 2025 (March 31)4holders −3
3new positions
6sold out
1famous investor
$1.13avg. 13F price*
At the end of Q1 2025, 4 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings, down 3 from Q4 2024. 3 opened new positions and 6 sold out. The largest holders were UBS Group AG ($26K), Two Sigma Securities, LLC ($16K) and Citadel Advisors ($15K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $46K |
| Exits | 6 | $56K |
All 13F filers, Q4 2024 → Q1 2025: 40,673 shares bought and 40,582 shares sold, net +91 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| UBS Group AG | 0.00% | Reduce -40.9% | 22,425 | $26K |
| Two Sigma Securities, LLC | 0.00% | New | 13,627 | $16K |
| Citadel Advisors | 0.00% | New | 13,539 | $15K |
| HRT Financial LP | 0.00% | New | 13,507 | $15K |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.